Berlin keynote details Eos SENOLYTIX's pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan.
Routine lab work helps establish a baseline, monitor metabolic and organ health, catch problems early, and show health factors beyond just the scale. Before prescribing an antiobesity medication, ...
Newspoint on MSN
HbA1c drops from 11.2% to 8.1%: Is diabetes under control? Doctor explains next steps
A reduction in HbA1c from 11.2% to 8.1% signals a meaningful improvement in average blood glucose levels. However, the lower ...
New Delhi: A fall in HbA1c from 11.2 per cent to 8.1 per cent can indicate significant improvement in blood glucose levels, ...
A 16-patient retrospective cohort found an association between finerenone initiation and lower urine albumin-to-creatinine ...
A dual-database pharmacovigilance analysis identified recurring renal and metabolic reporting signals for finerenone and ...
Weight loss alone does not explain all of the cardiovascular benefits observed with semaglutide 2.4 mg in the SELECT trial, ...
The global urinalysis market is valued at USD 4.2 billion in 2026 and is projected to reach USD 5.9 billion by 2031, growing at a CAGR of ...
Men's Journal on MSN
Don't Ignore Foamy Urine: It May Indicate Kidney Damage Before Symptoms Progress
Know what to watch for.
The FDA has approved Hibsago (bepirovirsen) as an add-on antisense oligonucleotide therapy to help noncirrhotic adults with chronic hepatitis B achieve functional cure.
Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month ...
A person may feel completely healthy, remain physically active and have no obvious urinary symptoms while kidney function gradually declines. By the time symptoms such as persistent fatigue, swelling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results